| Previous close | 2.4400 |
| Open | 2.4400 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 60.00 |
| Expiry date | 2024-08-16 |
| Day's range | 2.4400 - 2.4400 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GuruFocus.comInsider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK)
On June 17, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company.
GlobeNewswireCytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian participants. “We are conducting this Phase 1 bridging study to characterize the pharmacokinetics of aficamten in healthy Japanese adults and to gather evidence that we believe will be required for potential appr
GuruFocus.comInsider Sale at Cytokinetics Inc (CYTK) by EVP of Research & Development
Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 7,788 shares of the company on June 11, 2024.
